Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

euro adhoc: Sygnis Pharma AG
other
SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Research & Development
22.07.2007
Heidelberg, July 22nd, 2007 -  SYGNIS Pharma AG has successfully 
completed the clinical phase IIa-study (AXIS) in stroke. AXIS was a 
multicenter, doubleblind, placebo-controlled dose escalation study. 
The comprehensive analysis of the study data showed that the primary 
and secondary endpoints have been achieved and that the use of AX200 
in stroke patients can be considered to be safe.
Although the focus of the AXIS-study was the collection of data 
regarding safety and tolerability, data regarding the efficacy of 
AX200 were also monitored. Due to the small number of patients 
involved in such a safety study, a significant difference between 
AX200 and placebo treated patients could not be observed in the 
overall consideration of the usual clinical endpoints. However, a 
detailed statistical evaluation of the data provided hints that 
certain stroke patients may benefit from a treatment with AX200.
AX200 for the treatment of acute stroke is the most advanced drug 
candidate in SYGNIS´ product pipeline. Besides stroke, SYGNIS is 
currently preclinically testing the endogenous protein AX200 in 
further neurodegenerative indications such as Amyotrophic Lateral 
Sclerosis (ALS).
With the positive results of the AXIS study the path has been cleared
for the further clinical development of AX200. SYGNIS is now in the 
process of designing and preparing the phase IIb trial whose aim will
be to demonstrate the efficacy of AX200 in stroke patients.
###Except for the historical information contained herein, the 
matters set forth in this press release are forward looking. These 
forward-looking statements may include projections, assumptions, 
estimates, targets, and descriptions of future events. Such 
statements are based on currently available information and on 
SYGNIS´ current expectations as to future events that may not prove 
to be accurate. These statements are not guarantees of future 
performance and involve risks and uncertainties that are difficult to
predict. Many factors could cause the actual results, performance or 
achievements of SYGNIS to be materially different from those that may
be projected, expected, targeted, expressed or implied by such 
statements. ###
end of announcement                               euro adhoc 22.07.2007 15:41:40

Further inquiry note:

Dr. Franz-Werner Haas
Vice President Operations
Telefon: +49(0)6221 454-812
E-Mail: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG